- Report
- February 2024
- 70 Pages
Philippines
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
India
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 150 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
United States
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Spain
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Iran
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Australia
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2023
- 90 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- May 2026
- 200 Pages
Canada
From €2628EUR$2,789USD£2,188GBP
- Report
- July 2025
- 200 Pages
India
From €2628EUR$2,789USD£2,188GBP
- Report
- August 2026
- 70 Pages
Egypt
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 70 Pages
South Korea
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 120 Pages
Mexico
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Germany
From €4475EUR$4,750USD£3,726GBP
- Report
- February 2024
- 70 Pages
Italy
From €4475EUR$4,750USD£3,726GBP

Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more